$TARO News

Last published 1y ago

1y agoTAROTentative Approval of Doxepin, Anda #219058FDA Approved DrugsApproval Date: 03/13/2025; Drug Name: Doxepin, Anda #219058; Active Ingredients: DOXEPIN; Company: Taro Pharmaceutical Industries Ltd; Submission Status: Tentative Approval; Application Number: 219058
2y agoTAROSun Pharma Completes Taro MergerPR NewswireSun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
2y agoTAROTaro Shareholders Approve Merger with Sun PharmaPR NewswireSun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or...
2y agoTAROTaro Provides Results for Year Ended March 31, 2024Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to
2y agoTAROTaro to Release Full Year Results on May 20, 2024Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024. The release will be
2y agoTAROLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote "FOR" Taro Sun Pharma MergerBusiness WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass
2y agoTAROTaro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that it has called an extraordinary general meeting of its shareholders (the "Extraordinary General Meeting"), to be held on May
2y agoPGTI TAST TARO ANSSKuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoTAROKrensavage Asset Management Remains Opposed to Sun's Predatory Bid for TaroPR NewswireKrensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro...
2y agoTAROTaro Provides Results for December 31, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2023. Quarter ended December 31, 2023 Highlights
2y agoANSS PGTI TARO TASTKuehn Law Encourages TAST, ANSS, PGTI, and TARO Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoTAROTaro to Release Third Quarter Results on January 25, 2024Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25,
2y agoTAROTaro Announces Merger Agreement with Sun PharmaPR NewswireSun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or...
3y agoTAROTaro Provides Results for September 30, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and six months ended September 30, 2023. Quarter ended September 30, 2023 Highlights
3y agoTAROTaro to Release Second Quarter Results on October 26, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26,
3y agoMDWD SSKN TAROMediWound Reports Second Quarter 2023 Financial Results and Provides Company UpdateGlobeNewswireEscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid® U.S. commercial launch timing not
3y agoTAROTaro Provides Results for the Quarter Ended June 30, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2023. Quarter ended June 30, 2023 Highlights ─ compared to June 30,
3y agoTAROTaro to Release First Quarter Results on July 26, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The
3y agoTAROKrensavage Asset Management Opposes Sun's Lowball Bid for TaroPR NewswireNEW YORK, July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.'s paltry bid
3y agoTAROTaro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the "SEC"), is
3y agoTAROTaro Provides Results for Year Ended March 31, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─
3y agoTAROTaro to Release Full Year Results on May 23, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be
3y agoTAROTaro Provides Results for December 31, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2022. Quarter ended December 31, 2022*
3y agoTAROTaro to Release Third Quarter Results on January 24, 2023Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The
4y agoTAROTaro Provides Results for September 30, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and six months ended September 30, 2022. Quarter ended September 30, 2022*
4y agoTAROTaro to Release Second Quarter Results on October 27, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27,
4y agoTAROGalderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology PortfolioBusiness WireGalderma: Continued strong commercial and financial performance in a resilient market Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD Partic
4y agoTAROTaro Provides Results for the Quarter Ended June 30, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June 30, 2021 Net sales increased $
4y agoTAROTaro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission (the "SEC"), is available within the Investor Relations se
4y agoTAROTaro to Release First Quarter Results on July 27, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro's
4y agoTAROTaro Provides Results for the Year Ended March 31, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter
4y agoTAROTaro to Announce Full Year Results on May 26, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the year ended March 31, 2022, after the close of market on Thursday, May 26, 2022. The release will be accessible on Taro's website at
4y agoTAROTaro Completes Acquisition of AlchemeeBusiness WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today announced the completion of its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee's business and assets worldwide, including the
4y agoTAROTaro to Acquire Alchemee From GaldermaBusiness WireAlchemee's flagship brand Proactiv® is an iconic product synonymous with acne care Galderma and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") announced today they have signed a definitive agreement for Taro to acquire Alchemee, former
4y agoTAROTaro Provides Results for December 31, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and nine months ended December 31, 2021. Quarter ended December 31, 2021 Highlights ─ compared to December 31, 2020
4y agoTAROTaro to Announce Third Quarter Results on January 27, 2022Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2021, after the close of market on Thursday, January 27, 2022. The release will be acces
4y agoTAROTaro Appoints New Chief Financial OfficerBusiness WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today. Mr. Coote has over 25 years of significant financia
5y agoTAROTaro Provides Results for September 30, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and six months ended September 30, 2021. Quarter ended September 30, 2021 Highlights ─ compared to September 30, 20
5y agoTAROTaro to Announce Second Quarter Results on October 28, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2021, after the close of market on Thursday, October 28, 2021. The release will be acces
5y agoTAROTaro Provides Results for Quarter Ended June 30, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") today provided unaudited financial results for the quarter ended June 30, 2021. Quarter ended June 30, 2021 Highlights - compared to Quarter ended June 30, 2020 Net sales increased $29.5 m
5y agoTAROTaro to Announce First Quarter Results on July 27, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021. The release will be accessible on Taro's website
5y agoTAROTaro Announces Resignation of Chief Financial OfficerBusiness WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue ot
5y agoTAROTaro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission (the "SEC"), is available within the Investor Relations se
5y agoTAROTaro Provides Results for the Year Ended March 31, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2021. Quarter ended March 31, 2021 Highlights ─ compared to March 31, 2020 Net sales
5y agoTAROTaro to Announce Full Year Results on May 19, 2021Business WireTaro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021. The release will be accessible on Taro's website at www.taro.com. About Taro
5y agoTAROTaro Provides Results for December 31, 2020Business WireHAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2020.
5y agoTAROTaro to Announce Third Quarter Results on January 27, 2021Business WireHAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2020, after the close of market on Wednesday, January 27, 2021.
6y agoTAROTaro Provides Results for September 30, 2020Business WireHAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020.
6y agoTAROTaro to Announce Second Quarter Results on October 28, 2020Business WireHAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2020, on Wednesday, October 28, 2020.
6y agoTAROTaro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.Business WireHAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or “the Company”) today announced the launch of a new specialty generic, deferiprone, an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®. This pro ...